Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Multidrug resistance (MDR) in cancer chemotherapy is frequently caused by ATP-binding cassette (ABC) transporter overexpression, notably ABCB1.
• This efflux mechanism reduces the intracellular concentration of various anti-cancer drugs, leading to treatment failure.

Purpose of the Study:

• To design and synthesize novel inhibitors targeting ABCB1 to overcome multidrug resistance.
• To evaluate the efficacy of these compounds in blocking ABCB1-mediated drug efflux and enhancing anti-cancer drug accumulation.

Main Methods:

• Synthesis of 18 novel compounds based on a triazol-N-ethyl-tetrahydroisoquinoline scaffold.
• Evaluation of inhibitory activity against ABCB1.
• Assessment of compound efficacy in blocking drug efflux and increasing intracellular drug accumulation in MDR cells.

Main Results:

• Compounds with substitutions in para positions exhibited significant activity against ABCB1.
• Compound 5 demonstrated potent inhibition of ABCB1 drug efflux function.
• Compound 5 successfully increased the accumulation of anti-cancer drugs in MDR cells.

Conclusions:

• The novel triazol-N-ethyl-tetrahydroisoquinoline derivatives are promising candidates for overcoming ABCB1-mediated multidrug resistance.
• Compound 5 shows potential for enhancing the efficacy of cancer chemotherapy by restoring sensitivity in resistant tumors.